NASDAQ:DNAY

Telesis Bio (DNAY) Stock Forecast, Price & News

$1.40

+0.02 (+1.45%)

(As of 06/8/2023 ET)

Compare

Today's Range: $1.40
▼
$1.50
50-Day Range: $1.33
▼
$3.02
52-Week Range: $1.08
▼
$11.02

Volume: 23,231 shs
Average Volume: 54,063 shs
Market Capitalization: $41.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Telesis Bio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 257.1% Upside
$5.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.85) to ($1.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

432nd out of 986 stocks

Analytical Instruments Industry

13th out of 29 stocks

3.5

Analyst's Opinion

Consensus Rating
Telesis Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Telesis Bio has a forecasted upside of 257.1% from its current price of $1.40.
Amount of Analyst Coverage
Telesis Bio has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for DNAY.

0.0

Dividend Strength

Dividend Yield
Telesis Bio does not currently pay a dividend.
Dividend Growth
Telesis Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DNAY.

1.1

News and Social Media Coverage

Search Interest
1 people have searched for DNAY on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Telesis Bio to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Telesis Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
30.20% of the stock of Telesis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
42.66% of the stock of Telesis Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Telesis Bio are expected to grow in the coming year, from ($1.85) to ($1.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Telesis Bio is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Telesis Bio is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Telesis Bio has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Telesis Bio (NASDAQ:DNAY) Stock

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Receive DNAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter.

DNAY Stock News Headlines

May 12, 2023 | marketbeat.com

Blue Bird, First Solar rise; Harrow Health, Telesis Bio fall

Stocks that traded heavily or had substantial price changes Friday: Blue Bird, First Solar rise; Harrow Health, Telesis Bio fall

May 11, 2023 | investing.com

Telesis Bio Inc (TBIO)

June 9, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

April 12, 2023 | forbes.com

This Desktop Machine Is About To Transform The Decades-Old DNA Synthesis Industry

March 31, 2023 | marketwatch.com

Telesis Bio Shares Rise 10% After Release of Two New DNA Kits

March 22, 2023 | marketwatch.com

Telesis Bio Shares Climb 35% on 2023 Revenue Guidance

March 21, 2023 | sfgate.com

Telesis Bio: Q4 Earnings Snapshot

March 21, 2023 | finance.yahoo.com

Telesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance

June 9, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

March 16, 2023 | msn.com

Should You Buy Telesis Bio (TBIO) After Golden Cross?

March 14, 2023 | forbes.com

Synthetic Biology Startup Molecular Assemblies Ships First DNA From New San Diego Facility

January 3, 2023 | yahoo.com

Protalix BioTherapeutics Issues 2023 Letter to Stockholders

December 14, 2022 | uk.finance.yahoo.com

Telesis Bio, Inc. (DNAY)

November 21, 2022 | forbes.com

Can A Desktop DNA Printer Stomp Out The Next Pandemic?

November 12, 2022 | seekingalpha.com

Telesis Bio, Inc. (DNAY) Q3 2022 Earnings Call Transcript

November 11, 2022 | finance.yahoo.com

Telesis Bio, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

November 8, 2022 | finance.yahoo.com

Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

October 19, 2022 | finance.yahoo.com

Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument

October 4, 2022 | finanznachrichten.de

Codex DNA, Inc.: Codex DNA Expands Application of Proprietary Error Correction Technology

October 4, 2022 | finance.yahoo.com

Codex DNA Expands Application of Proprietary Error Correction Technology

September 28, 2022 | seekingalpha.com

DNAY Codex DNA, Inc.

September 26, 2022 | benzinga.com

Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, Netherlands

September 26, 2022 | finance.yahoo.com

Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, Netherlands

September 20, 2022 | finanznachrichten.de

Codex DNA, Inc.: Codex DNA Debuts Next-Generation Automated Synthetic Biology Workstation

September 19, 2022 | finance.yahoo.com

Codex DNA Debuts Next-Generation Automated Synthetic Biology Workstation

September 18, 2022 | nbcnews.com

More DNA sought from remains of possible Tulsa massacre victims

August 26, 2022 | finance.yahoo.com

Codex DNA (DNAY) Could Find Support Soon, Here's Why You Should Buy the Stock Now

See More Headlines

DNAY Price History

30 days | 90 days | 365 days | Advanced Chart

DNAY Company Calendar

Last Earnings: 11/08/2021
Today: 6/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DNAY
CUSIP: N/A
CIK: 1850079
Web: codexdna.com
Phone: 858-228-4115
Fax: N/A
Employees: 212
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +262.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,960,000.00
Net Margins: -251.04%
Pretax Margin: -250.94%
Return on Equity: -73.65%
Return on Assets: -51.19%

Debt

Debt-to-Equity Ratio: 0.37
Current Ratio: 4.86
Quick Ratio: 4.68

Sales & Book Value

Annual Sales: $21.04 million
Price / Sales: 1.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.10 per share
Price / Book: 0.45

Miscellaneous

Outstanding Shares: 29,522,000
Free Float: 20,606,000
Market Cap: $40.74 million
Optionable: Not Optionable
Beta: 1.36

Key Executives

Dr. Todd R. Nelson MBA (Age 55)
Ph.D., Pres, CEO & Director
Comp: $876.78k

Mr. Daniel G. Gibson Ph.D. (Age 45)
Chief Technology Officer
Comp: $436.54k

Mr. Eric Esser (Age 52)
Chief Operating Officer

Richard Lepke
Director of Investor Relations

Mr. Robert H. Cutler (Age 54)
Chief Legal Officer

Ms. Laura B. Puga M.B.A. (Age 42)
VP of People & Culture

Mr. Decky Goodrich M.B.A.
Sr. VP of Commercial Operations

Mr. Brent M. Hunter
Exec. Officer

Mr. Laurence Warden
Sr. VP of Engineering & Instrumentation

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

DNAY Stock - Frequently Asked Questions

Should I buy or sell Telesis Bio stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Telesis Bio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DNAY shares.
View DNAY analyst ratings or view top-rated stocks.
What is Telesis Bio's stock price forecast for 2023?: 1 equities research analysts have issued 1-year target prices for Telesis Bio's stock. Their DNAY share price forecasts range from $5.00 to $5.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 262.3% from the stock's current price.
View analysts price targets for DNAY or view top-rated stocks among Wall Street analysts.
How have DNAY shares performed in 2023?: Telesis Bio's stock was trading at $1.20 at the start of the year. Since then, DNAY stock has increased by 15.0% and is now trading at $1.38.
View the best growth stocks for 2023 here.
How were Telesis Bio's earnings last quarter?: Telesis Bio, Inc. (NASDAQ:DNAY) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.06. The business had revenue of $2.79 million for the quarter, compared to the consensus estimate of $2.93 million. Telesis Bio had a negative net margin of 251.04% and a negative trailing twelve-month return on equity of 73.65%.
When did Telesis Bio IPO?: (DNAY) raised $100 million in an IPO on Friday, June 18th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and KeyBanc Capital Markets acted as the underwriters for the IPO.
What is Telesis Bio's stock symbol?: Telesis Bio trades on the NASDAQ under the ticker symbol "DNAY."

Who are Telesis Bio's major shareholders?: Telesis Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Penn Capital Management Company LLC (1.84%), Penbrook Management LLC (1.16%), Renaissance Technologies LLC (0.32%), Vontobel Holding Ltd. (0.17%), Susquehanna International Group LLP (0.00%) and Two Sigma Investments LP (0.08%).
How do I buy shares of Telesis Bio?: Shares of DNAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Telesis Bio's stock price today?: One share of DNAY stock can currently be purchased for approximately $1.38.
How much money does Telesis Bio make?: Telesis Bio (NASDAQ:DNAY) has a market capitalization of $40.74 million and generates $21.04 million in revenue each year. The company earns $-38,960,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.
How many employees does Telesis Bio have?: The company employs 212 workers across the globe.
How can I contact Telesis Bio?: The official website for the company is codexdna.com. The company can be reached via phone at 858-228-4115 or via email at ir@codexdna.com.

This page (NASDAQ:DNAY) was last updated on 6/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Telesis Bio (DNAY) Stock Forecast, Price & News

Telesis Bio MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Telesis Bio (NASDAQ:DNAY) Stock

DNAY Stock News Headlines

DNAY Price History

DNAY Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

DNAY Stock - Frequently Asked Questions

Overall MarketRank^™